Skip to main content
Signal8
Launch Terminal

Jade Biosciences, Inc. (JBIO)

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Jade Biosciences, Inc. logo

Jade Biosciences, Inc.

NASDAQ:JBIOHealthcare
-1.26%$14.06
AH$14.06+0.00%vs close
Mkt Cap$894.18M
Float54.08M
O/S63.6M
Vol
$ Vol
RVOL
Inst Own-
SI20.7%
Earnings
Dilution
Jade Biosciences, Inc. logoNASDAQ:JBIO$14.06-1.26%
Phase Distribution
8 lead-sponsored trials·4 active·0 completed
Phase 13
Phase 21
Phase 2/31
Phase 32
Not applicable1
Status Overview
Not yet recruiting1
Recruiting3
Active, not recruiting1
Stopped2
Unknown1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Terminated

    Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)

    AV-101

    Pulmonary Arterial Hypertension

    Enrollment
    186
    Start
    Nov 2022
    Primary Completion
    Aug 2024
    Completion
    Aug 2024
    NCT05557942
  • Phase 3
    Not yet recruiting

    A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy

    JADE101, Placebo

    IgA Nephropathy (IgAN)

    Enrollment
    480
    Start
    Dec 2026est.
    Primary Completion
    Jun 2029est.
    Completion
    Sep 2030est.
    NCT07902817
  • Phase 2/3
    Terminated

    A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

    AV-101, Placebo

    Pulmonary Arterial Hypertension

    Enrollment
    202
    Start
    Dec 2021
    Primary Completion
    Aug 2024
    Completion
    Aug 2024
    NCT05036135
  • Phase 2
    Recruiting

    A Study of JADE101 in Participants With Immunoglobulin A Nephropathy

    JADE101

    IgA Nephropathy

    Enrollment
    30
    Start
    May 2026
    Primary Completion
    Jan 2029est.
    Completion
    Apr 2029est.
    NCT07541287
  • Phase 1
    Active, not recruiting

    A Phase 1 Study of JADE101 in Healthy Participants

    JADE101, Placebo

    Healthy Volunteers

    Enrollment
    32
    Start
    Aug 2025
    Primary Completion
    Oct 2026est.
    Completion
    Oct 2026est.
    NCT07059312
  • Phase 1
    Recruiting

    A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants

    JADE101

    Healthy Volunteers (HV)

    Enrollment
    40
    Start
    May 2026
    Primary Completion
    May 2027est.
    Completion
    May 2027est.
    NCT07525947
  • Phase 1
    Recruiting

    A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis

    JADE201, Placebo

    Rhematoid Arthritis

    Enrollment
    36
    Start
    May 2026
    Primary Completion
    Oct 2027est.
    Completion
    Oct 2028est.
    NCT07533955
  • Observational
    Unknown status

    Validation of the JADE wRAP™, a Novel Blood Pressure Measurement Device, Using the Same Arm Sequential Method

    -

    Blood Pressure

    Enrollment
    140
    Start
    Dec 2017
    Primary Completion
    Dec 2021est.
    Completion
    Dec 2021est.
    NCT03452280
Search ClinicalTrials.gov for “Jade Biosciences”